hVIVO shares rise 11% as influenza trial win and rebrand signal integrated strategy bearing fruit

hVIVO PLC (AIM:HVO) shares rose 11% to 8.18p after the clinical development specialist announced a new influenza human challenge trial contract and unveiled a unified brand identity on the same day, marking what the company says is the completion of its transformation into a fully integrated drug development partner. The trial agreement with Traws Pharma will see hVIVO test tivoxavir marboxil, an investigational single-dose oral antiviral targeting seasonal influenza and bird flu, at its Canary Wharf quarantine facilities.